TELA Bio, Inc. Announces Adele Oliva Not to Stand for Re-Election to the Board at the AGM
April 22, 2021 at 07:17 am EDT
Share
On April 16, 2021, Adele Oliva, a member of the Board of Directors of TELA Bio, Inc. notified the Company of her intent to not stand for re-election to the Board at the Company's 2021 Annual Meeting of Stockholders (the "Annual Meeting") and, as a result, her term will end upon the conclusion of the Annual Meeting on June 2, 2021. Ms. Oliva will also resign from her position as member and chair of the Nominating and Corporate Governance Committee of the Board. Ms. Oliva's decision to resign did not result from any disagreement with the Company on any matters relating to the Company's operations, policies or practices.
TELA Bio, Inc. is a commercial-stage medical technology company. The Company is focused on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patientâs own anatomy. Its first portfolio of products, the OviTex Reinforced Tissue Matrix (OviTex), addresses unmet needs in hernia repair and abdominal wall reconstruction. Its OviTex portfolio consists of multiple product configurations intended to address various surgical procedures within hernia repair and abdominal wall reconstruction, including ventral, inguinal, and hiatal hernia repair. The Company's OviTex products include OviTex 1S, OviTex 2S, and OviTex LPR. Its second portfolio of products, the OviTex PRS Reinforced Tissue Matrix (OviTex PRS), addresses unmet needs in plastic and reconstructive surgery. OviTex PRS is indicated for use in implantation to reinforce soft tissue where weakness exists in patients requiring soft-tissue repair.
TELA BIO, INC. 
